- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
- Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
- Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
- Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
- Immuneering to Participate in the Cowen 44th Annual Health Care Conference
- Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
More ▼
Key statistics
On Thursday, Immuneering Corp (IMRX:NMQ) closed at 1.77, 1.14% above its 52-week low of 1.75, set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.89 |
---|---|
High | 1.89 |
Low | 1.76 |
Bid | 1.75 |
Offer | 1.84 |
Previous close | 1.86 |
Average volume | 643.11k |
---|---|
Shares outstanding | 29.28m |
Free float | 20.63m |
P/E (TTM) | -- |
Market cap | 54.47m USD |
EPS (TTM) | -1.89 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼